Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Consensus PT from Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has earned an average rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $9.50.

Several equities analysts recently issued reports on QNCX shares. Brookline Capital Management assumed coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective for the company. RODMAN&RENSHAW raised Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Rodman & Renshaw started coverage on shares of Quince Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $11.00 target price for the company. Finally, Maxim Group initiated coverage on shares of Quince Therapeutics in a research report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price target on the stock.

Quince Therapeutics Price Performance

QNCX stock opened at $1.99 on Thursday. The firm has a 50 day moving average of $1.82 and a 200-day moving average of $1.12. The company has a market cap of $87.56 million, a price-to-earnings ratio of -1.60 and a beta of 0.64. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45.

Institutional Investors Weigh In On Quince Therapeutics

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC increased its position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 339,125 shares of the company’s stock after acquiring an additional 66,170 shares during the quarter. Geode Capital Management LLC owned approximately 0.78% of Quince Therapeutics worth $263,000 as of its most recent filing with the SEC. 30.75% of the stock is currently owned by institutional investors and hedge funds.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.